基亞生物科技股份有限公司/Medigen Biotechnology Corp.
基亞生物科技股份有限公司/Medigen Biotechnology Corp.
  • About
    • Company Overview
    • Our Vision
    • Corporate Structure
    • Corporate Governance
      • Board of Directors
      • Remuneration Committee
      • Organization and Operation of Internal Audit
      • Corporate Governance Status
      • Corporate Regulations
      • Corporate Social Responsibility Status
    • Management
    • Careers
    • Subsidiaries
      • Medigen Vaccine Biologics Corporation
      • TBG Diagnostics Limited
      • Winston Medical & Biotech Group
  • Cell Therapy
    • MAGICELLl–NK (Natural killer cells)
    • MAGICELL®-GDT​(T cells)
    • GTP certificated cell processing facility
    • Cell Therapy Cooperation Agency
    • Cell Therapy Regulation in Taiwan
  • COVID-19
  • CLINICAL TRIALS
    • Product Pipelines
    • NK CELL (MAGICELL-NK)
    • OBP-301 (Telomelysin)​
  • NEWS
    • Material Information
      • 2025
      • 2024
      • 2023
      • 2021
    • Financial Statement
    • Shareholder Services
  • Investors
    • Financial Statements
      • Monthly Revenue Statement
      • Quarterly and Annual Report
    • Shareholder Services
      • Share Price
      • Shareholder Meeting Document
    • Contact Information
    • Stakeholders
  • Language
    • 中文 (繁)
    • English
    • 中文 (简)

Blog

Home | NEWS | The construction of vaccine plant for Medigen Vaccinology Corp. in Hsinchu Biomedical Park is nearly completed.

The construction of vaccine plant for Medigen Vaccinology Corp. in Hsinchu Biomedical Park is nearly completed.

0
By MEDIGENADMIN
2014-10-23
NEWS

  • News
  • Financial Statement
  • Shareholder Services
previous postnext post
14F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C)‧Copyright© 2021-2025 Medigen Biotechnology Corp. All rights reserved.